Kornimate/medical-research-clean huggingface dataset:
cardiopulmonary assesments in mood disorders

Conditions: Mood Disorders; Physical Inactivity; Respiratory Function Impaired

Summary: the importance of cardiorespiratory impact in mental diseases is generally emphasized in studies, but it is noteworthy that cardiorespiratory affects in mood disorders have not been sufficiently investigated. this study aims to compare individuals with mood disorders and healthy people in terms of exercise capacity, functionality, respiratory muscle strength, respiratory functions, dyspnea and physical activity level.

the cross-sectional study was carried out with 30 patients with diagnosis of mood disorder who applied to the hatay mustafa kemal university research and practice hospital, mental health and diseases clinic, and 35 healthy individuals whose age, gender were matched. clinical characteristics, exercise capacity (6-minute walking test, 6mwt; 3-minute step test, 3mst), functionality (vertical jump test, functional reach test), respiratory parameters (respiratory muscle strength, pulmonary function test), dyspnea (modified medical research council, mmrc scale), physical activity level (short form international physical activity questionnaire, ipaq) was evaluated.

Eligibility criteria:
inclusion criteria: * healthy volunteers who had undergone a general physical examination in the past 6 month * reported being free of significant cardiovascular, respiratory, neuromuscular, and endocrine disorders that preclude safe participation exclusion criteria: * individuals with significant cardiovascular, neuromuscular and endocrine disorders, * pregnant women, * people under 18 years old * disabled individuals.
autologous bone marrow derived mesenchymal stromal cells (bm-mscs) in patients with chronic kidney disease (ckd)

Conditions: Chronic Kidney Disease

Summary: this study was designed to provide confirmation of safety of mesenchymal stem cells (mscs) therapy in chronic kidney disease (ckd).

we will assess the 18-month safety and potential efficacy of autologous mscs as a therapy for ckd. a total of 10 patients with ckd iv injection of high doses 2×106/kg of autologous mscs t, which will be derived from biopsies of their bone marrow. assessments will be performed at 1, 3, 6, 12 and 18 months after cell injection. changes in glomerular filtration rate (gfr) were evaluated by scan isotope.

Eligibility criteria:
inclusion criteria: * male and female * ckd symptoms * ckd confirmed with serum and urine analysis and gfr 25-60 ml/min/1.73 m2 * patient's age between 25 - 60 years * ability to understand and willingness to sign consent from exclusion criteria: * pregnant or lactating * basis disease such as diabetes, malignancy and autoimmune * unable to follow post-operative exercise regimen or return for evaluations

Keywords: autologous bone marrow mesenchymal stem cells chronic kidney disease
two-piece zirconia dental implant vs two-piece titanium dental implant- randomized clinical control trial

Conditions: Osseointegration Failure of Dental Implant Due to Infection; Osseointegration Failure of Dental Implant Prior to Intentional Prosthetic Loading

Summary: 2 arms (60 subjects - 30 each arm). experimental group with two-pice zirconia dental implant and control group with two-piece titanium dental implant evaluate changes in inflammatory and microbiology levels from t0 (baseline) t2 (8 weeks) and t3 (after crown placement) also evaluate secondary outcomes: marginal bone loss (mbl), gingival height (gh) levels, osseointegration, gender, age, time of surgery, anatomical position and implant stability. p values\<0.05 were considered statistically significant


Eligibility criteria:
inclusion criteria: single implants in any area (maxillary and mandibular), extracted teeth for at least 3 months before implant placement, with bone volumes sufficient (at least 2 mm mesial, distal, buccal and palatal) to accommodate dental implant without the need for regeneration. controlled oral hygiene, absence of any lesions in the oral cavity, at least 2 mm keratinized tissue. in addition, patients must agree to participate in a postoperative control program and signed the informed consent. exclusion criteria: 1 - allergic to local anaesthetics, or any of the other components. 2 - patients with hepatic or renal dysfunction 3 - patients with epilepsy, shock, cardiac conduction disorders or myasthenia gravis 4 - patients with myocardial injury 5 - hyperthyroidism 6 - severe hypertension 7 - insufficient bone volume 8 - smoking more than five cigarettes / day 9 - excessive alcohol consumption 10 - localized anti-tumour radiation therapy of the oral cavity 11 - chemotherapy 12 - liver diseases 13 - immunosuppressed patients 14 - patients taking corticosteroids 15 - pregnancy 16 - inflammatory and autoimmune diseases of the oral cavity -
study of the effects of a new antidepressant therapy in patients with major depressive disorder (mdd)

Conditions: Depressive Disorder, Major

Summary: the purpose of this study is to assess the efficacy, safety and tolerability of gw679769 patients with major depressive disorder (mdd).


Eligibility criteria:
inclusion criteria: * primary diagnosis of major depressive disorder as defined in dsm-iv. * capable of giving informed consent and willing to comply with the study requirements. * women of childbearing potential must agree to one of a number of defined acceptable methods of birth control. exclusion criteria: * primary diagnosis within the past 6 months of another axis 1 disorder such as an anxiety disorder. * use of medications for a psychiatric condition including herbals in the past 2-12 weeks according to medication type. * subjects who, in the investigator's judgement, pose a current, serious suicidal or homicidal risk or have made a suicide attempt within the past 6 months. * subjects who currently meet or who met within 6 months prior to screening dsm-iv criteria for substance abuse or subjects who currently meet or who met within 6 months prior to screening dsm-iv criteria for substance dependence (other than nicotine). * significantly abnormal blood or urine laboratory tests or electrocardiogram (ecg).

Keywords: depression major depressive disorder mdd
adult bipolar mania

Conditions: Acute Mania

Summary: the purpose of this study is to determine if lithium 600-1800 mg/day is effective when added to quetiapine fumarate extended release (quetiapine xr or seroquel® xr) 400-800 mg/day in treating acute mania and if so, how it compares with placebo (a non-active capsule, like a sugar pill, that looks like lithium).


Eligibility criteria:
inclusion criteria: * provision of informed consent before any study procedures are performed. * the patient must have a documented clinical diagnosis for bipolar i disorder, including recent episode manic or mixed, and being male of females age 18-65 years, inclusive. * patients may be outpatients or inpatients at enrollment visit, but all patients must be inpatients when randomized and remain inpatients until discharged at the discretion of the investigator. exclusion criteria: * the patient can not have had up to 8 mood episodes during the past 12 months and not been continuously hospitalized for acute bipolar for up to 3 weeks immediately before participating in the study. * the patient can not have a past diagnosis of stroke or medically documented transient ischemic attacks (tia) or a history of seizure disorder, except for febrile convulsions. * the patient must not have received electroconvulsive treatment (ect) within 90 days before participating in the study and in the doctors judgement pose a current suicidal or homicidal risk.

Keywords: acute mania mania, adults seroquel acute mania in adult patients
online mindfulness-based intervention on parents of children with attention deficit/hyperactivity disorder

Conditions: Pilot Study

Summary: this project apply curriculum of online programme materials and structure for mindful parenting and caregiving. it will include four modules (introductory mindfulness, mindful parenting, applying mindfulness in challenging moments, and advanced exercises for parents of children with special needs). each module will include short psychoeducation videos and audio mindfulness exercises that can be used in various web-based or application-based platforms. a set of videos and audio exercises will be produced for the core program materials. one study of online mindful parenting program reported a low completion rate below 30%, showing the significance of weekly video or phone contact by professionals in program engagement. although web-based or application-based mindfulness intervention have become popular, very limited effort has been developed for applying mindfulness in parenting and caregiving using technology. only two published studies on online mindfulness-based intervention for parents are identified. objectives of the study are: 1. investigate the effects of online mindfulness-based intervention for parents of children with attention deficit/hyperactivity disorder. 2. validate the protocol of the programme and explore the needs to make refinements of the programme based on the quantitative outcome and qualitative interview analyses


Eligibility criteria:
inclusion criteria: * parents whose children are between 6 and 18 years old and diagnosed with attention deficit/hyperactivity disorder * parents can understand and speak cantonese chinese, and * participants should be the primary caretaker of the children in the last one year exclusion criteria: * parents who were diagnosed with psychosis, developmental disabilities, or cognitive impairment, which may present difficulties in comprehending the content of the program, * parents have had prior experience in any 8-week mindfulness-based stress reduction/mindfulness-based cognitive therapy or equivalent program.

Keywords: adhd parent mindfulness-based intervention online
hepatitis b vaccine booster study (v232-058)(completed)

Conditions: Hepatitis B

Summary: to assess the safety and immunogenicity of a booster dose of hepatitis b vaccine in children who have received a 3-dose primary series of either recombivax hb or engerix-b. the primary vaccination series (was given 4 to 8 years prior to study entry and consisted of a licensed hepatitis b vaccine product (either recombivax hb or engerix-b). the booster dose given in this study will be either an investigational merck product (modified process hepatitis b vaccine) or licensed engerix-b vaccine.


Eligibility criteria:
inclusion criteria: * healthy children 4 to 8 years of age * complete medical records documenting receiving a previous hepatitis b vaccination during the first year of life (for cohort a and b only) * complete 3-dose vaccination with either a primary series of recombivax hb or a primary series of engerix-b (for cohort a and b only) exclusion criteria: * birth mother known to be a carrier of hepatitis b virus (cohort c only) * history of previous hepatitis b vaccine * history of vaccination with any hepatitis b vaccine (cohort c only) * known of suspected hypersensitivity to any component of recombivax hb or engerix-b (eg aluminum, yeast) recent administration of hepatitis b immune globulin (hbig), serum immune globulin, or any other blood-derived product * receipt of investigational drugs or vaccines within 3 months prior to study vaccine or planned within study period * impairment of immunologic function or recent use of immunomodulatory medications * a combination of different hepatitis b vaccines used in the primary vaccination series (cohort a and b only)
the influence of porcelain fused to metal ( pfm) and zirconia crowns on periodontal health

Conditions: Periodontitis

Summary: investigate the influence of the crown tye porcelain fused to metal or zirconia on periodontal health.

porcelain fused to metal (pfm) has been used in dentistry for the last five decades. zirconia (zirconium oxide, zro2) is the white crystalline powder oxide of the naturally occurring metal zirconium. research of the medical utilization of zirconia dates back to the late 1960s. however, its utilization in dentistry did not start until the 1990s, when zirconia began to be used as a form of endodontic posts and implant abutments. the current literature contains studies that investigated the influence of zirconia implants and abutments on periodontal tissue, but to the investigators' knowledge, no work has been yet published which compares the influences of crown types on hard and soft tissues. this prospective study will be conducted in the department of periodontology and in the department of maxillofacial rehabilitation at rambam health care campus.

Eligibility criteria:
inclusion criteria: 1. patient age 18 - 85 years old 2. in need for one or more fixed partial prosthetic crown or bridge exclusion criteria: 1. smokers 2. active periodontal disease 3. history of compromising systemic disease 4. allergy to materials used in the study 5. current drug abuse 6. pregnant or intend to become pregnant 7. severe salivary gland dysfunction 8. severe medical complications ( organ transplants, cancer, immunocompromised, or undergoing long-term antibiotic or steroid therapy )
pilot study of the qi device for monitoring of patients with congestive heart failure

Conditions: Heart Failure

Summary: the present study proposes to utilize a novel, wearable device, qi device, which has multiple sensors embedded in a "wrist-watch" in order to explore its monitoring capabilities in individuals with congestive heart failure.

the qi device is a self-contained, reusable, rechargeable, battery-powered, wrist-watch that simultaneously tracks and records a number of physiological health related parameters such as heart rate, blood pressure, respiratory rate, temperature, and motion/position. one advantage of this device over current home diagnostic systems is the capability for longitudinal monitoring.

Eligibility criteria:
inclusion criteria: * adults over age 18 * own, and comfortable using, a home computer with internet access (phase 2 only) * acute hospitalization with a primary diagnosis of acute decompensated heart failure (adhf) diagnosed on the basis of all of the following: 1. symptoms: * onset or worsening of dyspnea within the past 2 weeks 2. physical exam (at least 1 present): * rales/ crackles on auscultation * elevated jvp \> 10 cmh2o * weight gain * le edema 3. diagnostic imaging/ labs (at least 1 present): * evidence of pulmonary congestion or edema on chest x-ray/ chest ct * elevated bnp or nt-pro-bnp (age-adjusted) exclusion criteria: * psychological or social situation that would make the study difficult for the patient * inability to consent * chronic atrial fibrillation or other dysrhythmia with a high (\>10%) burden of ectopic beats. * pregnant women * pneumonia - currently, or within the past 30 days * non-cardiogenic pulmonary edema (e.g. ards) * interstitial lung disease * end-stage renal disease and on hemodialysis

Keywords: wearable device wrist-watch longitudinal monitoring congestive heart failure
characterization of novel lipoprotein properties associated with an increased risk to develop atherosclerosis

Conditions: Atherosclerosis

Summary: objectives of medical research: separation of ldl and hdl from blood samples of patients with high ldl and / or low hdl who have developed atherosclerotic disease with similar patients who have no evidence of atherosclerosis. lipidomics and proteomics will examine whether there is a difference in lipid and protein composition and lipoprotein composition. if there are any changes in expression level or the composition of proteins or metabolites that make up lipoproteins, the investigator will try to figure out the mechanism responsible for these changes and their role in the metabolic process. the investigator will seek therapeutic measures through which these mechanisms can be inhibited and thus inhibit the development of sclerosis or even retraction.

participants: participants who are found suitable during their visit to the lipid institute clinic or during hospitalization at the sheba medical center will receive an explanation of the study, will be asked to sign a consent form. a medical history will be taken, the participant will be asked to fill out a nutrition questionnaire (ffq) and a 5 cc blood sample will be taken from each patient

Eligibility criteria:
inclusion criteria: * healthy participants with ldl levels less than 130 mg / dl without evidence of atherosclerosis or wall thickening of the carotid artery according to an ultrasound imaging of the carotid artery at the lipid institute and unknown for atherosclerosis or cardiovascular disease in the background. * participants with ldl levels above 160 mg / dl, with no evidence of atherosclerosis or wall thickening of the carotid artery according to an ultrasound - imt of the carotid arteries performed at the lipid institute and unknown for atherosclerosis or cardiovascular disease in the background. * participants with ldl levels above 160 mg / dl, where evidence of atherosclerosis or wall thickening of the arteries can be found by ultrasound imaging of the carotid artery that is performed at the lipid institute or known for atherosclerosis or cardiovascular disease in the background. exclusion criteria: * patients with triglyceride values above 300 mg%, hdl lower than 30 mg%, apob greater than 150 mg% or lpa higher than 70 mg% will not be included in the study
endocan predictive value in postcardiac surgery acute respiratory failure.

Conditions: Respiratory Failure; Postoperative Complications

Summary: according to literature data, endocan can detect the onset of respiratory failure. the investigators aim to prove its value also for cardiac surgery patients.

endocan is an endothelium derived soluble dermatan sulfate proteoglycan. literature data shows that alterate levels of its blood concentration correlate with the onset of pulmonary failure in patients with major trauma and septic shock. in cardiac surgery respiratory failure and infections are threatening complications leading to mortality rates up to 80%. a rapid diagnosis and treatment of this pathology is crucial to improve the clinical outcome. unfortunately specific data for the efficacy of endocan predictive value in cardiac surgery patients are not available. the investigators aim to determinate if endocan can be a helpful tool to identify patients developing acute respiratory failure after cardiac surgery and anticipate specific treatment in order to improve survival.

Eligibility criteria:
inclusion criteria: * able to give written consent * elective cardiac surgery * more than 18 years old exclusion criteria: * less than 18 years old * urgency / emergency cardiac surgery * pregnancy * refusal * unable to give written consent * oncologic patients * concomitant inflammatory or infective pulmonary disease
efficacy of gut-brain neuromodulators for functional dyspepsia

Conditions: Functioanl Dyspepsia

Summary: the use of neuromodulators is now recognized by international consensus as effective in improving disorders of gut-brain interaction (dgbis). however, the digestive mind-body concept of therapeutic drugs is still in the experience-based treatment stage, and there is a lack of clinical studies in the field of dgbis. although numerous studies have been conducted to confirm the safety of neuromodulators for the treatment of dgbis, the current functional dyspepsia (fd) treatment is still awaiting further explorations and accumulations. in addition, neuromodulators, like flupentixol-melitracen (fm), are often used as a second-line treatment option for fd after the failure of acid-suppressive therapy with proton pump inhibitors, etc. however, the efficacy of conventional drugs for fd is mediocre, which often leads to recurrent and prolonged symptoms, seriously affecting patients' confidence in treatment and their quality of life, and the repeated visits to the clinic also create a huge economic burden for the society. therefore, we conducted a clinical trial to verify whether fm can be used as the first-line therapy to improve the efficacy of fd patients.


Eligibility criteria:
inclusion criteria: 1. adult patients with primary fd who meet the diagnostic criteria for roman iv; 2. able to complete the questionnaire, trial evaluation and sign the written informed consent. exclusion criteria: 1. organic gastrointestinal diseases by gastroenteroscopy within 6 months; 2. severe insufficiency of heart, liver, kidney, lung and other important organs and with congenital diseases; 3. allergic to the drugs used in this study 4. being pregnant, lactating or planning to become pregnant; 5. are taking or have taken monoamine oxidase inhibitors within the past 5 weeks; 6. have a known risk of narrow angle glaucoma.
enhancing panic and smoking reduction treatment with d-cycloserine

Conditions: Nicotine Addiction; Panic Attack

Summary: the purpose of the current study is to evaluate the efficacy of d-cycloserine in augmenting treatment of smoking cessation for individuals with panic attacks. the investigators hypothesize that individuals receiving dcs (versus those receiving placebo) will evidence greater smoking abstinence rates and decreased panic symptoms after receiving a combined cbt-based treatment for smokers with panic attacks.


Eligibility criteria:
inclusion criteria: * male and female patients ages 18-65 capable of providing informed consent * willing and able to provide informed consent, attend all study visits and comply with the protocol * daily smoker for at least one year * currently smoke an average of at least 8 cigarettes per day * report a motivation to quit smoking in the next month of at least 5 on a 10-point scale * evidence of panic attack within the past year and endorsement of smoking as an emotion regulation strategy (i.e., score at least a 78 on the saeq). exclusion criteria: * subjects who do not use smoking as an emotion regulation strategy * current diagnosis of a psychotic, eating, developmental or bipolar disorder * significant suicide risk as determined by structured interview * pregnant women, lactating women, and women of childbearing potential who are not using medically accepted forms of contraception (e.g., iud, oral contraceptives, barrier devices, condoms and foam, or implanted progesterone rods stabilized for at least 3 months). * psychoactive substance abuse or dependence (excluding nicotine dependence) within the past 6 months * current use of isoniazid or ethionamide compounds * a history of significant medical condition and/or be deemed as currently unhealthy in the context of a complete physical examination * limited mental competency and the inability to give informed, voluntary, written consent to participate * current use of any pharmacotherapy or psychotherapy for smoking cessation not provided by the researchers during the quit attempt * concurrent psychotherapy initiated within three months of baseline, or ongoing psychotherapy of any duration directed specifically toward treatment of anxiety or mood disorder other than general supportive therapy initiated at least 3 months prior to the study * use of other tobacco products * plans to move outside of the immediate area in the next six months * insufficient command of the english language